Xiaoyi Chong

64PUBLICATIONS

246CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)MechanobiologyPredictive and prognostic markersImmunogenetics (incl. genetic immunology)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (64)

Sort by Publication Date:

|Jun 04, 2026

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

|Mar 12, 2026

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Zhi Peng, Yanqiao Zhang, Huiting Xu

|Feb 02, 2026

Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial.

Bohan Zhang, Lei Zhang, Cheng Liu

|Dec 29, 2025

Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study.

Panpan Zhang, Miao Zhang, Yakun Wang

|Dec 20, 2025

A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.

Ran Xue, Miaoyan Wei, Jiajia Yuan

|Dec 12, 2025

EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy.

Jing Gao, Xi Jiao, Fang Ren

Pageof 11

Frequent Collaborators

Jian Li

Ruihua Xu

Panpan Zhang

Ming Lu

Roberto Pazo-Cid

Cheng Zhang

Zhihao Lu

Shukui Qin

Jun Zhang

Xianjun Yu

Frequent Collaborators

Jian Li

Ruihua Xu

Panpan Zhang

Ming Lu